How do I install the Icsm Defer Tt Elevated Psa Or Nodules skill?

Run npx skillmds@latest add dromlakhani/icsm-defer-tt-elevated-psa-or-nodules in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Icsm Defer Tt Elevated Psa Or Nodules safe to use?

This skill has not completed SkillMD's automated safety review yet. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Icsm Defer Tt Elevated Psa Or Nodules?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Icsm Defer Tt Elevated Psa Or Nodules free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Icsm Defer Tt Elevated Psa Or Nodules?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Icsm Defer Tt Elevated Psa Or Nodules by dromlakhani

Name: Icsm Defer Tt Elevated Psa Or Nodules
Rating: 4.2 (5 reviews)
Author: dromlakhani

Icsm Defer Tt Elevated Psa Or Nodules

Recommends postponing testosterone initiation and pursuing MRI or biopsy when PSA is elevated or a prostate nodule is detected on digital rectal examination; if evaluation shows no cancer, testosterone therapy may be considered. Triggered by clinician findings of elevated PSA (>4 ng/mL) or a palpable prostate nodule during DRE, prompting the question of whether to hold testosterone until prostate cancer is ruled out.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Defer testosterone therapy until prostate evaluation if PSA elevated or nodules present

STEP 1 — Gather Information

Collect symptoms of hypogonadism, obtain morning total testosterone, perform digital rectal examination (DRE), and measure serum PSA.
→ Proceed to evaluate PSA and DRE findings.

STEP 2 — Rule In / Rule Out

Is PSA >4 ng/mL (or age‑adjusted threshold) or is a prostate nodule palpable on DRE?

If yes → proceed to Step 3.
If no → testosterone therapy may be considered after confirming hypogonadism.
→ Decision based on PSA/DRE results.

STEP 3 — Classify or Stratify

If PSA elevated or nodule present, obtain prostate MRI and/or targeted biopsy to rule out malignancy.
→ Proceed to prostate imaging/biopsy.

STEP 4 — Decide

If evaluation shows no cancer, testosterone therapy may be initiated; if cancer is diagnosed, refer to oncology and defer testosterone.
→ Initiate testosterone only after negative prostate evaluation; otherwise refer for cancer management.

Clinical Guardrails / Mimics / Pitfalls

Do not start testosterone in men with elevated PSA or nodule without urologic assessment; do not rely on PSA alone without DRE; do not ignore nodules; consider that PSA can be elevated by BPH, infection, or recent ejaculation; ensure biopsy is performed if MRI suspicious; avoid testosterone in known prostate cancer.

Concrete Clinical Example

A 58‑year‑old man presents with low libido and morning total testosterone 8 nmol/L. DRE reveals a firm nodule and PSA is 5.2 ng/mL. Testosterone is deferred; prostate MRI shows a suspicious lesion, biopsy confirms benign prostatic hyperplasia. After negative evaluation, testosterone therapy is started.

Source: Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., 2025, DOI: 10.1093/sxmrev/qeaf036

---name: icsm-defer-tt-elevated-psa-or-nodulesdescription: Recommends postponing testosterone initiation and pursuing MRI or biopsy when PSA is elevated or a prostate nodule is detected on digital rectal examination; if evaluation shows no cancer, testosterone therapy may be considered. Triggered by clinician findings of elevated PSA (>4 ng/mL) or a palpable prostate nodule during DRE, prompting the question of whether to hold testosterone until prostate cancer is ruled out.---# Defer testosterone therapy until prostate evaluation if PSA elevated or nodules present## STEP 1 — Gather InformationCollect symptoms of hypogonadism, obtain morning total testosterone, perform digital rectal examination (DRE), and measure serum PSA. → Proceed to evaluate PSA and DRE findings.## STEP 2 — Rule In / Rule OutIs PSA >4 ng/mL (or age‑adjusted threshold) or is a prostate nodule palpable on DRE? - If yes → proceed to Step 3. - If no → testosterone therapy may be considered after confirming hypogonadism. → Decision based on PSA/DRE results.## STEP 3 — Classify or StratifyIf PSA elevated or nodule present, obtain prostate MRI and/or targeted biopsy to rule out malignancy. → Proceed to prostate imaging/biopsy.## STEP 4 — DecideIf evaluation shows no cancer, testosterone therapy may be initiated; if cancer is diagnosed, refer to oncology and defer testosterone. → Initiate testosterone only after negative prostate evaluation; otherwise refer for cancer management.## Clinical Guardrails / Mimics / PitfallsDo not start testosterone in men with elevated PSA or nodule without urologic assessment; do not rely on PSA alone without DRE; do not ignore nodules; consider that PSA can be elevated by BPH, infection, or recent ejaculation; ensure biopsy is performed if MRI suspicious; avoid testosterone in known prostate cancer.## Concrete Clinical ExampleA 58‑year‑old man presents with low libido and morning total testosterone 8 nmol/L. DRE reveals a firm nodule and PSA is 5.2 ng/mL. Testosterone is deferred; prostate MRI shows a suspicious lesion, biopsy confirms benign prostatic hyperplasia. After negative evaluation, testosterone therapy is started.**Source:** Male hypogonadism: recommendations from the Fifth International Consultation on Sexual Medicine (ICSM 2024), Mohit Khera et al., 2025, DOI: 10.1093/sxmrev/qeaf036

Frequently asked questions